NEW YORK (GenomeWeb) – Becton Dickinson reported today that its fiscal fourth quarter revenues rose 6 percent year over year, driven by strong growth in its medical segment that was partly offset by flat revenue growth in the diagnostics business.  

For the three months ended Sept. 30, the company posted revenues of $3.23 billion compared to $3.06 billion in the year-ago quarter, beating Wall Street analysts' average estimate of $3.22 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.